Efficacy of a Topically Applied Spot-on Formulation of Metaflumizone Combined with Amitraz (Promeris® for Dogs) Against Paralysis Tick (Ixodes holocyclus) on Dogs in Australia
World Small Animal Veterinary Association World Congress Proceedings, 2007
Merete Holm-Martin

Twenty-six dogs, hyper immunized against holocyclotoxin, 1 to 9 years of age and weighing from 25.0 to 46.0 kg, were ranked within gender in descending order of tick carrying capacity and randomly allocated to Groups A, B and C. Ten to eleven unfed adult female Ixodes holocyclus were manually attached to each dog on Days -1, 7, 14, 21 and 28. On Day 0, Group B dogs were treated with the test formulation Promeris for Dogs (15% w/v metaflumizone and 15% w/v amitraz). Group C dogs were treated with the positive control formulation Frontline®Plus, Merial (100 g/L fipronil and 90 g/L (S)-methoprene). Group A remained the untreated control group. Ticks were counted for 3 days following treatment or tick attachment. Ticks were classified according to viability (healthy/ sick/ dead). The test product, Promeris for Dogs, provided more rapid efficacy than the commercial formulation, Frontline®Plus, in controlling pre-existing infestations with 93.4% efficacy versus 39.4% efficacy on Day 1. The persistent activity of the test product versus the control product was 100% versus 98.8% on Day 3; 100% versus 100% on Day 10; 100% versus 100% on Day 17; 96.1% versus 61.9% on Day 24 and 86.2% versus 51.7% on Day 31 when calculated by geometric mean of healthy attached ticks. It was concluded that in this study the test product Promeris for Dogs was safe and efficacious in controlling I. holocyclus on dogs for up to 21 days post-treatment.

®Frontline is a registered trademark of Merial.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Merete Holm-Martin
Fort Dodge Animal Health
NSW, Australia


MAIN : Abstracts - Oral : Spot-On Metaflumizone & Amitraz
Powered By VIN

Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27